STEM cell scientists have developed a more accurate way of identifying aggressive forms of bowel cancer, which should eventually lead to better treatment and survival rates.
The UK-led team, headed by scientists from Durham University and the North East England Stem Cell Institute, (NESCI*), studied tissue samples from 700 colorectal cancer patients and tracked their progress.
They found that patients who had a stem cell marker protein called Lamin A present in their tissue were more likely to have an aggressive form of the disease.
The team concluded that if the marker is detected in the early forms of colorectal cancer, these patients should be given chemotherapy in addition to the surgery normally offered to ensure a better survival predicament.
The team now aims to develop a robust prognostic tool for use in the health service.
The study, funded by the Association for International Cancer Research and NHS Research and Development funds, is published in the open-access scientific journal PLoS ONE.
The Durham University/NESCI scientists worked with colleagues from The James Cook University Hospital, Middlesbrough, and the Departments of Pathology and Epidemiology at the University of Maastricht in the Netherlands.
Bowel cancer is the third most common cancer in the UK, where each year more than 36,000 people are diagnosed with the disease. Worldwide over a million new cases of bowel cancer were diagnosed in 2002.
Almost three-quarters of bowel cancer cases occur in people aged 65 and over. The development of disease is linked with diet, lifestyle and environmental factors. (Source of statistics: Cancer Research UK fact sheet).
In colorectal cancer, there are four key stages of the disease. The stage of a patient's cancer is determined by a series of hospital tests, the results of which inform the treatment they are given.
In the two earlier stages, before the cancer involves the lymph nodes, patients normally have an operation to remove the cancer from the bowel. They are rarely given chemotherapy in addition to the surgery. This is because for many patients, who are often elderly and frail, chemotherapy may cause more harm than benefit. It's therefore critical to know when and in whom it should be used.
However, the new study suggests that around one third of these patients will express the Lamin A stem cell marker, which indicates a more serious form of the cancer. These patients, argue the scientists, should be given chemotherapy to target these stem cells, which should ultimately improve their recovery and survival rates.
Professor Chris Hutchison, of Durham University and NESCI, said: "Currently the hospitals use a standard test to work out how far the cancer has progressed and then they use this to determine the treatment the patient should receive. However, we are potentially able to more accurately predict who would benefit from chemotherapy."
Dr Stefan Przyborski, of Durham University and NESCI, said: "We now aim to carry out more work in this area to develop a prognostic tool which we hope will eventually be for widespread use by the health services in the treatment of bowel cancer."
Professor Robert Wilson, a consultant surgeon and bowel cancer specialist at The James Cook University Hospital, Middlesbrough, said: "We have a very high number of patients with bowel cancer in the north east of England in particular. We know the best treatment for very early and very late disease but there are still a lot of unknowns in-between these two extremes.
"Chemotherapy can be very useful but can have a number of side effects, so we only want to use it where we think there's a good chance it will help. This test will help us determine that."
* 'The North-east England Stem Cell Institute (NESCI) draws together Durham and Newcastle Universities, the Newcastle-upon-Tyne Hospitals NHS Foundation Trust and other partners in a unique interdisciplinary collaboration to convert stem cell research and technologies into cost-effective, ethically-robust 21st century health solutions to ameliorate degenerative diseases, the effects of ageing and serious injury. The Institute has received substantial funding and other support from the Regional Development Agency, One NorthEast and is partly based at the International Centre for Life in Newcastle.' http://www.nesci.ac.uk/
MEDIA INFORMATION:
Interviews:
- Professor Chris Hutchison: +44(0) 191 334 1270; Availability: 2pm-5pm Tuesday August 19; 9-2pm Wednesday August 20. Or contact Durham University Media Relations Office +44(0) 191 334 6075; media.relations@durham.ac.uk
- Prof Robert Wilson, consultant surgeon, The James Cook University Hospital, Middlesbrough: Contact the hospital's Public Relations Department: Lesley Connor: +44(0) 1642 854 343.
Images– available from Durham University media relations office:
- North News pictures of Prof Chris Hutchison and Dr Stefan Przyborski in a laboratory setting
- A head shot of Prof Robert Wilson
- Scientific image from the paper: This shows bowel cancer tissue stained for the presence of the stem cell marker lamin A. (The top four panels show cancers that are negative for lamin A and these patients showed high rates of survival. The bottom four panels show cancers that were positive for lamin A and these patients showed poor rates of survival).
Contact:
Durham University Media Relations Office:
Tel: +44(0) 191 334 6075
Email: media.relations@durham.ac.uk
Web: www.durham.ac.uk/news
Citation: Willis ND, Cox TR, Rahman-Casañs SF, Smits K, Przyborski SA, et al. (2008) Lamin A/C Is a Risk Biomarker in Colorectal Cancer. PLoS ONE 3(8): e2988. doi:10.1371/journal.pone.0002988
PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT (URL live from Aug 20): http://dx.plos.org/10.1371/journal.pone.0002988
PRESS-ONLY PREVIEW: http://www.plos.org/press/pone-03-08-hutchison.pdf
Disclaimer
The following press release refers to an upcoming article in PLoS ONE. The release has been provided by the article authors and/or their institutions. Any opinions expressed in this are the personal views of the contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.
Journal
PLoS ONE